Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Spago Nanomedical AB is a biotechnology company focused on the development of nanomedicines for cancer diagnostics and therapy. The company emphasizes the use of nanotechnology to enhance the precision and effectiveness of treatments and diagnostic tools, particularly in oncology. One of Spago Nanomedical's primary objectives is to improve magnetic resonance imaging (MRI) techniques through the creation of contrast agents that enhance the visualization of tumors. This advancement serves to facilitate early detection and improve the management of cancer. Spago Nanomedical operates within the bio-pharmaceutical industry, where it plays a pivotal role in innovating oncology care solutions and enhancing diagnostic accuracy. With a commitment to cutting-edge research and development, Spago Nanomedical continues to make advancements that contribute significantly to modern medical practices and the larger health sector.
kr 0.01
kr 0.00 (-2.27%)
EOD Jun 26, 2026 · Twelve Data
The business is unprofitable at the operating level (-6059.27% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 77.1% YoY. Margins deteriorated 4295.1pp alongside, both lines moving the wrong way.
Negative free cash flow of -kr 29M. The business is consuming cash, not generating it. Operating margin contracted 4295.1pp YoY, cost discipline may be slipping.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 437K
▼ -77.1% YoY
Net Income (TTM)
-kr 27M
▲ +18.3% YoY
Op. Margin
-6059.27%
▼ -4295.1pp YoY
ROIC
-65.39%
▲ +6.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 29M
▲ +17.7% YoY
Op. Cash Flow (TTM)
-kr 28M
▲ +19.5% YoY
Net Debt
-kr 30M
Net Cash Position
Cash & Equiv.
kr 30M
3Y CAGR: -25.4%
Continue Research
Spago Nanomedical AB (SPAGO.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Spago Nanomedical AB scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Spago Nanomedical AB scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -6,059.3% operating margin and a -65.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh SPAGO.XSTO's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.